Noonan syndrome-causing genes: Molecular update and an assessment of the mutation rate  by El Bouchikhi, Ihssane et al.
Q6
+ MODEL
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
IJPAM84_proof ■ 17 August 2016 ■ 1/10
International Journal of Pediatrics and Adolescent Medicine (2016) xx, 1e1061
62
63
64
65
66
67
68
69
70
71
HOSTED BY Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.elsevier .com/locate/ i jpamREVIEW ARTICLE72
73
74
75
76
77
78
79
80
81
82
83
84
85Noonan syndrome-causing genes: Molecular
update and an assessment of the mutation
rate
Ihssane El Bouchikhi a,b,*, Khadija Belhassan a,
Fatima Zohra Moufid a,b, Mohammed Iraqui Houssaini b,
Laila Bouguenouch a, Imane Samri a, Samir Atmani c,
Karim Ouldim a86
87
88
89
90
91
92
93a Medical Genetics and Oncogenetics Laboratory, HASSAN II University Hospital, BP 1835, Atlas,
Fez 30000, Morocco
b Laboratory of Microbial Biotechnology, Faculty of Sciences and Techniques,
University of Sidi Mohammed Ben Abdellah, B.P. 2202, Route d’Imouzzer, Fez 30000, Morocco
c Medico-Surgical Unit of Cardio-pediatrics, Department of Pediatrics, HASSAN II University Hospital,
BP 1835, Atlas, Fez 30000, Morocco94
95Received 15 April 2016; accepted 14 June 201696
97
98
99
100
101
102
103
104
105
106
107KEYWORDS
Molecular etiology;
MAP kinase signaling
pathways;
Mutation rate;
Noonan syndrome;
PTPN11;
RAS familyAbbreviations: CDC25, cell division cyc
activating protein; GDP, guanosine-DiP
hypertrophic cardiomyopathy; IGF-1,
* Corresponding author. Medical Gene
E-mail address: ihssane.elbouchikh
Peer review under responsibility o
108
109
110
111
112
Please cite this article in press as: E
mutation rate, International Journal
http://dx.doi.org/10.1016/j.ijpam.20
2352-6467/Copyrightª 2016, King Fais
by Elsevier B.V. This is an open accesAbstract Noonan syndrome is a common autosomal dominant disorder characterized by short
stature, congenital heart disease and facial dysmorphia with an incidence of 1/1000 to 2500
live births. Up to now, several genes have been proven to be involved in the disturbance of
the transduction signal through the RAS-MAP Kinase pathway and the manifestation of Noonan
syndrome. The first gene described was PTPN11, followed by SOS1, RAF1, KRAS, BRAF, NRAS,
MAP2K1, and RIT1, and recently SOS2, LZTR1, and A2ML1, among others. Progressively, the
physiopathology and molecular etiology of most signs of Noonan syndrome have been demon-
strated, and inheritance patterns as well as genetic counseling have been established. In this
review, we summarize the data concerning clinical features frequently observed in Noonan
syndrome, and then, we describe the molecular etiology as well as the physiopathology of most
Noonan syndrome-causing genes. In the second part of this review, we assess the mutational
rate of Noonan syndrome-causing genes reported up to now in most screening studies. This re-
view should give clinicians as well as geneticists a full view of the molecular aspects of Noonan
syndrome and the authentic prevalence of the mutational events of its causing-genes. It willle 25; CHD, congenital heart defects; CR, conserved region; CRD, cysteine-rich domain; GAP, GTPase
hosphate; GEF, guanine exchange factor; GTP, guanosine-TriPhosphate; GH, growth hormone; HCM,
insulin-like growth factor I; RBD, RAS binding domain; REM, RAS exchange motif.
tics and Oncogenetics Unit, Hassan II University Hospital, Fez 30000, Morocco. Tel.:(þ212) 610 36 75 09 Q2 Q3.
i@usmba.ac.ma (I. El Bouchikhi).
f King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia.
113
114
115
116
117
118
119
120
121
122
l Bouchikhi I, et al., Noonan syndrome-causing genes: Molecular update and an assessment of the
of Pediatrics and Adolescent Medicine (2016), http://dx.doi.org/10.1016/j.ijpam.2016.06.003
16.06.003
al Specialist Hospital & Research Centre (General Organization), Saudi Arabia. Production and hosting
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2 I. El Bouchikhi et al.
+ MODEL
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
IJPAM84_proof ■ 17 August 2016 ■ 2/1064
65
66
67
68
Please cite this article in press as: E
mutation rate, International Journalalso facilitate lay the groundwork for future molecular diagnosis research, and the develop-
ment of novel treatment strategies.
Copyright ª 2016, King Faisal Specialist Hospital & Research Centre (General Organization),
Saudi Arabia. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
1231. Introduction
Noonan syndrome ([NS1, OMIM 163950]) is a common
autosomal dominant disorder characterized by short stat-
ure, congenital heart disease and facial dysmorphia and
other features such as cryptorchidism, bleeding diathesis,
skeletal malformations and mild cognitive delays with var-
iable expressivity. The prevalence of this disorder is esti-
mated to be 1/1000e2500 live births [1e3]. The varied
clinical manifestations observed in Noonan syndrome pa-
tients (facial, skeletal cardiac, and hematological, among
others) are a result of the involvement of the RAS MAP ki-
nase molecular signaling pathway, as will be shown below.
The previous updates and reviews in the literature have
thoroughly discussed Noonan syndrome, often focusing on
diagnostic evaluations, clinical guidelines, and manage-
ment with treatment options, which have amply helped
clinicians provide the best care for Noonan syndrome chil-
dren. The molecular aspects of this disorder have been
approached in these reviews progressively with genetic
advances. However, considering the fast advances and
consecutive progress being made in the physiopathology
and genetic studies of Noonan syndrome, it seems impor-
tant to gather these findings in one paper to help the
audience of clinicians and geneticists have a full view of
recent advances in the molecular etiology of Noonan syn-
drome, as well as an authentic prevalence of the muta-
tional rates of its causing-genes. Therefore, this review
provides, in the first part, an update on the molecular
aspect of the disease, in which we summarize the data
concerning clinical features frequently observed, then
focus on the molecular etiology, the inheritance pattern
and the genetic counseling that should be given to patients.
In the second part of this review, we establish and discuss
the mutational rate reported up to now in most genes
involved in Noonan syndrome.
2. Review
2.1. Clinical features and diagnosis
The diagnosis of Noonan syndrome is based primarily on the
clinical features that have been established from the very
beginning through several clinical studies that have metic-
ulously defined the criteria and signs of diagnosis [1e3].
2.1.1. Dysmorphic face
The extreme variability of facial traits in Noonan syndrome
from one individual to another makes the assessment of
frequency difficult and not very meaningful. Furthermore,
the dysmorphic signs could change within the same patientl Bouchikhi I, et al., Noonan synd
of Pediatrics and Adolescent Meddepending on his/her age, to be less perceptible in adult-
hood than earlier in childhood. The dysmorphology is
characterized during the postnatal period by a tall fore-
head, low-set-posteriorly-rotated ears, a thickened helix,
nerve deafness, hypertelorism, ptosis, down slanting
palpebral fissures, epicanthal folds, deeply grooved phil-
trum, a high arched palate and triangular face, with a low
posterior hairline and webbed neck. In adulthood, the
facial features become more subtle, the eyes are less
prominent, with a slightly elongated neck, wrinkled skin
and high anterior hairline [3e5].
2.1.2. Congenital heart defect
The cardiac features are well delineated and are estimated
to be present in 50% up to 90% of Noonan syndrome patients
[6e8]. The most common congenital heart defects (CHD)
are pulmonic stenosis (50e60%), hypertrophic cardiomy-
opathy (HCM) (20%) and atrial septal defect (6e10%) [9,10].
The other CHDs such as ventricular septal defect, atrio-
ventricular canal defect, and aortic coarctation are
observed less frequently [6,8,11]. Electrocardiographic
abnormalities were reported in 87% of patients [3]. Elec-
trocardiograms display wide QRS complexes with a pre-
dominant negative pattern in the left precordial leads, a
left axis deviation and giant Q waves [9e11].
2.1.3. Growth/short stature
Weight and height are normal at birth. However, during
childhood and at puberty, short stature becomes a promi-
nent common sign of Noonan syndrome. In one series re-
ported by Nora et al, the prevalence of Noonan children
with height below the 3rd percentile is approximately 83%
[12]. In another study, pubertal growth was found to be
delayed by almost two years and the mean height was in
the 3rd percentile, with female and male average heights
of 151 cm and 161 cm, respectively, and the average bone
age delayed by two years [8].
2.1.4. Skeletal defects
A chest deformity characterized by superior pectus car-
inatum and inferior pectus excavatum is observed in up to
95% of Noonan syndrome patients. Half (50%) have cubitus
valgus and 30% have a clinobrachydactyly. The other or-
thopedic features, such as thoracic scoliosis, talipes equi-
novarus or radiolunar synostosis, are observed less often
[3,7].
2.1.5. Bleeding defect
The coagulation defect is the most common hematologic
disorder in Noonan syndrome patients. Approximately 55%
of patients have mild to moderate abnormal bleeding,
whereas only 3% have major abnormal bleeding [3].124
rome-causing genes: Molecular update and an assessment of the
icine (2016), http://dx.doi.org/10.1016/j.ijpam.2016.06.003
Q1
Figure 1 Localization of Noonan syndrome causing genes
into the RAS-MAP kinase signal transduction pathway.
Noonan syndrome-causing genes 3
+ MODEL
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
IJPAM84_proof ■ 17 August 2016 ■ 3/102.1.6. Genito-urinary
Altered spermatogenesis and cryptorchidism are observed
in 60e80% of patients [13]. Ten percent of patients have
renal abnormalities that often include renal pelvis dilata-
tion [3].
2.1.7. Ophthalmological features
Approximately 55% of Noonan syndrome patients have an
abnormal ophthalmological test [3]. The frequent abnor-
malities are refractive errors (61e70%), strabismus
(48e63%), amblyopia (33%) and anterior segment changes
(63%) [14,15].
2.1.8. Other features
Other features have also been reported, including lympha-
tic abnormalities, hematological malignancy, giant cell le-
sions and cognitive disability, among others [16e19].
2.2. Genetic diagnosis and molecular etiology
As shown above, Noonan syndrome is a heterogeneous dis-
order with various clinical features ranging from facial
dysmorphology to short stature and bleeding defects up to
congenital heart disease. Those features have been
demonstrated by several studies to be the yield of
diverse molecular and physiological mechanisms, some of
which are well known, while others need to be further
elucidated.
The molecular etiology of Noonan syndrome has been
established first by the study of two large Noonan syndrome
families using linkage analysis [20e22]. These studies sug-
gested that the concerned locus is located in the 12q24
region. Based on these data, and the data suggesting the
involvement of SHP-2 in the signaling pathways that control
semilunar valvulogenesis [23], and by means of a positional
candidacy approach, Tartaglia et al [24] suggested PTPN11
to be a Noonan syndrome candidate gene, and confirmed
this hypothesis by bidirectionally sequencing the fifteen
exons of PTPN11, which have shown mutations in 50% of the
studied cohort.
2.2.1. PTPN11 (protein-tyrosine phosphatase,
nonreceptor-type 11)
The PTPN11 gene ([OMIM 176876]) (Fig. 2A) is organized into
three domains: the N-amino terminal src-homology 2
domain (N-SH2) and the phosphotyrosine phosphatase (PTP)
domain, which are the most commonly mutated domains;
and the C-amino terminal src-homology 2 domain (C-SH2)
and carboxy-terminal tail [25,26].
Protein SHP-2 coded by PTPN11 was demonstrated to be
involved in several developmental processes such as limb
development, semilunar valvulogenesis, hemopoietic cell
differentiation and mesodermal patterning [23,27e29], and
is widely expressed in several tissues such as the heart,
muscles, and brain, in which SHP-2 modulates the cellular
proliferation, migration or differentiation processes during
the developmental stage [30]. SHP-2 is a key element of the
signaling molecular RAS-MAP Kinase cascade (Fig. 1). The
latter is triggered when cytokines, hormones or growth
factors bind to membrane receptors [25,26,31]. Therefore,
its disturbance may cause alterations of these tissues thatPlease cite this article in press as: El Bouchikhi I, et al., Noonan synd
mutation rate, International Journal of Pediatrics and Adolescent Medlead to the aberrant phenotype shown in Noonan syndrome
patients. This fact has been confirmed by De Rocca et al,
who that the SHP-2 mutations in Noonan syndrome were
associated with the inhibition of GH-induced IGF-1 via the
hyperactivation of RAS/ERK1/2 in a mouse model, which
lead to the short stature observed in Noonan syndrome
[32].
On the molecular level, SHP-2 is a cytosolic phosphatase
protein activated by the binding of a N-SH2 domain to
phosphotyrosyl residue, which leads to the conformational
change making the catalytic site (PTP) available to the
phosphotyrosyl residue. In the absence of substrate, SHP-2
regains its inactive form in which N-SH2 interacts with PTP
to hide the catalytic site [33].
Most of the PTPN11 mutations causing Noonan syndrome
manifestations cluster in these two domains. The energy-
based structured analysis suggests that PTPN11 mutations
disrupt the inactive conformation, resulting in the emer-
gence of the catalytic site, which triggers the phospho-
tyrosyl phosphatase activity in the absence of the ligand
[24].
Additionally, several screening studies were carried out
to define PTPN11 mutations in other populations and
to highlight putative novel mutations. PTPN11 mutations
were significantly correlated to the manifestation of pul-
monary stenosis, which was observed in 45e70% of cases
[34,35].
Seven other genes from the RAS-MAP kinase pathway
(Fig. 1) were demonstrated to be mutated and to cause
Noonan syndrome.
2.2.2. SOS1 (Son of Sevenless homolog 1)
At present, SOS1 ([OMIM 182530]) is considered the second
molecular cause of Noonan syndrome. Roberts et al
reported that SOS1 is responsible for approximately 20% of
Noonan syndrome patients in the absence of PTPN11 mu-
tations [36].
SOS1 is a guanine exchange factor (GEF) with a major
role in the RAS-MAP kinase pathway. It is mapped on therome-causing genes: Molecular update and an assessment of the
icine (2016), http://dx.doi.org/10.1016/j.ijpam.2016.06.003
Figure 2 Organization of Noonan syndrome causing genes and domains, A. PTPN11 exons and SHP-2 domains, B. SOS1 exons and
domains, C. KRAS coding exons and domains. In most cases, the exon 4a is spliced out. D. RIT1 coding exons and domains. E. RAF1
coding exons and domains with the localization of Ser259 and Ser621 residues that is critical for RAF1 auto-inhibition. F. BRAF
coding exons and domains. G. MAP2K1 coding exons and domains. C-SH2: C-amino-terminal src-homology 2, CR: Conserved Region,
CRD: Cysteine-Rich Domain, DH: Dbl Homology, HF: Histone-like Fold, HL: Helical Linker, N-SH2: N- amino-terminal src-homology 2,
PH: Pleckstrin Homology, Pr: Proline-riche motif, PTP: protein-tyrosine phosphatase, RBD: RAS binding domain, REM: RAS Exchange
Motif, Sw: Switch.
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IJPAM84_proof ■ 17 August 2016 ■ 4/102p22-p21 region and consists of 23 exons (Fig. 2B) [37,38]
coding for multiple domains containing: histone-like folds
domain (HF), Dbl homology domains (DH) and Pleckstrin
homology domains (PH) with the following regulatory
function; RAS exchanging motif (REM) and Cdc25 domains
with catalytic function; helical linker (HL) relating PH and
REM, and the PolyProline region [36,39].
It was reported that Noonan syndrome-causing SOS1 was
associated with a high prevalence of ectodermal abnor-
malities [36,39e41].
In the RAS-MAP kinase molecular cascade, RAS protein is
inactivated by hydrolyzing GTP to GDP via GTPase Acti-
vating Protein (GAP). To be reactivated, RAS protein needs
to exchange bound GDP for GTP via SOS1.
It was suggested that the Dbl homology domain inhibits
RAS-GEF activity by competing with RAS for binding to the
REM-Cdc25 complex designated as an allosteric site, which
stabilizes the inactive conformation [42].
Most mutations cluster in these domains and lead to
gain-of-function in the RAS-MAP kinase pathway by dis-
rupting the auto-inhibition of SOS1 RAS-GEF activity
[36,39,43].
Pulmonic stenosis was more frequently observed in pa-
tients with SOS1 mutations (83.3%) than in those with
PTPN11 mutations [34].Please cite this article in press as: El Bouchikhi I, et al., Noonan synd
mutation rate, International Journal of Pediatrics and Adolescent MedThe RAS family (KRAS, HRAS, NRAS and RIT1) is a small
GTPase protein family responsible of signal propagation
through the RAS-MAP kinase cascade. It acts as a molecular
switch cycling between an inactive GDP bound conforma-
tion and an active GTP bound conformation (Fig. 1) [44,45].
2.2.3. KRAS (kirsten rat sarcoma viral oncogene homolog)
The KRAS ([OMIM 190070]) gene is mapped to the 12p12
region, and consists of 6 exons coding for the P loop, and
switch I and switch II domains (Fig. 2C) [46]. In response to
a transduction signal generated from membrane receptor
binding, KRAS regains its active bound GTP conformation
via the guanine nucleotide exchange factor, and entails an
activation cascade through the downstream effectors of
RAS-MAP kinase (such as RAF1). KRAS has intrinsic GTPase
activity, which, supported by RAS-GAPs (RAS-GTPase acti-
vating protein), hydrolyzes bound GTP to GDP to inactive
itself [44,45].
Lee et al and Schubbert et al have reported that KRAS
mutations cause approximately 5% of Noonan syndrome
cases in the absence of PTPN11 mutations [34,47]. These
mutations lead to a gain in the function effect through the
RAS-MAP kinase pathway by altering the intrinsic GTPase
activity of KRAS and creating insensitivity to RAS-GAPs
[46,47].rome-causing genes: Molecular update and an assessment of the
icine (2016), http://dx.doi.org/10.1016/j.ijpam.2016.06.003
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reported to have severe phenotypes with severe mental
retardation [46e48].
2.2.4. NRAS (neuroblastoma RAS viral oncogene homolog)
The NRAS ([OMIM 164790]) gene mapped on 1p13.2 com-
prises 6 coding exons [49]. Cirstea et al have reported that
NRAS mutations are involved in less than 1% of Noonan
syndrome cases [50].
2.2.5. RIT1(Ric-like protein without Caax motif 1)
Interestingly, in 2013, Aoki et al reported that mutations in
RIT1 ([OMIM 609591]) cause Noonan syndrome [51]. RIT1 is a
member of the RAS subfamily of small GTPases (Fig. 1) [52],
and consists of 6 exons and is located in the 1q22 region
(Fig. 2D).
Aoki et al identified nine missense mutations in seven-
teen individuals from 180 patients (9%) with Noonan syn-
drome or related disorders and without mutations in known
Noonan syndrome-causing genes, and observed that the
frequency of RIT mutations in the Noonan syndrome cohort
was seemingly similar to the frequency of RAF1 mutations.
This finding was subsequently confirmed by Bertola et al, in
2014, who found the same prevalence (9%), and Gos et al,
in 2014, who found a lower mutation rate (3.8%). Those
mutation clusters in the G1, Switch I, and more frequently
in Switch II domains, were proven to entail a significant
activation of the RAS MAPK pathway by hyper-activating
transcription factor ELK1. [51,53,54].
Noonan syndrome patients with RIT1 mutations were
characterized by a high incidence of congenital heart dis-
ease (94%), especially hypertrophic cardiomyopathy (71%)
and pulmonic stenosis (65%). The frequency of hypertrophic
cardiomyopathy among RIT1 mutation-positive patients is
similar to that of RAF1 mutation-positive subjects with
Noonan syndrome, which leads to the conclusion that RIT1
and RAF1 interact with each other and have the same ef-
fect on cardiac development [51,55,56].
The RAF family (ARAF, BRAF and RAF1) has an activation
role upstream of the MEK-ERK cascade into the RAS-MAPK
pathway (Fig. 1).
2.2.6. RAF1 (v-raf-1 murine leukemia viral oncogene
homolog 1)
RAF1 ([OMIM 164760]) mutations cause 3e17% of Noonan
syndrome cases. RAF1 consists of 17 exons coding for
multidomain protein that act as a serineethreonine kinase
(Fig. 2E) [55,57,58]. This protein comprises three conserved
regions (CR): CR1 that contains the RAS binding domain
(RBD) and cysteine-rich domain (CRD), which are both
suggested to be involved in the negative regulation of RAF1
by direct physical interaction [59]; CR2, which is an
important region in which lays many RAF1-activating mu-
tations and clusters. Eighty percent 80of RAF1 mutations in
Noonan syndrome have HCM. It contains Ser259 residue,
which is critical to RAF1 auto-inhibition [55]; and the third
conserved region (CR3) in the C-terminal region of RAF1
that is responsible for catalytic activity [55,57]. The RAF1
inactive conformation is maintained via 14-3-3 protein di-
mers that bind to phosphorylated Ser259 and Ser621 in such
a way that the catalytic site remains hidden [60]. Mutations
in these conserved residues or in its flanking residues (suchPlease cite this article in press as: El Bouchikhi I, et al., Noonan synd
mutation rate, International Journal of Pediatrics and Adolescent Medas Arg256 and Pro261, among others) prevent the 14-3-3
binding leading to an auto-inhibition fail and the activation
of the RAS-MAP kinase cascade [57].
Noonan syndrome-causing RAF1 mutations were strongly
correlated to hypertrophic cardiomyopathy. The latter was
observed in 95% of Noonan syndrome patients, and seems to
have an allele specificity that is associated with Ser259 and
Ser612 mutations (P < .0001) [57].
In 2015, De Iriarte Rodrıguez et al proved that reduced
levels of RAF1 in mice may lead to hearing impairments
[61].
2.2.7. BRAF (V-Raf murine sarcoma viral oncogene
homolog B1)
BRAF ([OMIM 164757]), a member of the RAF family, was
proven to be involved in Noonan syndrome pathogenesis by
enhancing ERK activation [55,62]. However, the frequency
of these mutations reported in a large cohort screening of
Noonan syndrome patients were lower than those observed
in RAF1, approximately 1.7e1.9%. These mutations cluster
predominantly in conserved regions of CR1 and CR3
(Fig. 2F), but modestly increase kinase activity compared to
RAF1 [34,63].
2.2.8. MAP2K1 (mitogen activated protein kinase 1)
MAP2K1 ([OMIM 176872]) is mapped to the 15q22 region and
comprises 11 exons encoding the MEK protein, which is a
dual-specificity kinase with a major protein kinase domain
that activates the extracellular-signal-regulated (Erk)
mitogen-activated protein (MAP) kinases (Fig. 2G) [64].
Previous studies confirmed that MEK plays a crucial role
in the embryonic developmental process, especially in cell
migration and placental development [64]. In 2007, Nava
et al identified MAP2K1 mutations in 4.2% of Noonan syn-
drome patients who are negative for PTPN11 and SO1
mutations [65]. This finding proved that mutations in the
MEK protein kinase domain increase MEK basal kinase
activity. This hyperactivity entails an increased phos-
phorylation of the downstream targets (such as ERK1 and
ERK2) [66].
Recently, with the progress of molecular screening tools,
whole genome sequencing (WGS) and whole exome
sequencing (WES) have become increasingly used in the
screening of developmental diseases. As a result, several
novel Noonan syndrome-causing genes were highlighted in
the last two years.
2.2.9. SOS2 (Son of Sevenless homolog 2)
In 2015, Yamamoto et al reported that SOS2 ([OMIM
601247]), the homolog of SOS1, is responsible of 4% of
Noonan syndrome cases with no mutation in the genes
previously associated with Noonan syndrome. SOS1 and
SOS2 are 70% homologous. The reported mutations cluster
in the DH domain, which plays a pivotal role in the stabi-
lization of inactive conformation. Similar to SOS1, these
mutations were associated with ectodermal defects [67].
2.2.10. LZTR1 (leucine-zipper-like transcription
regulator 1)
In the same study, Yamamoto et al identified pathogenic
mutations in a candidate gene not associated with the RAS/
MAPK pathway, the LZTR1 gene ([OMIM 600574]). Therome-causing genes: Molecular update and an assessment of the
icine (2016), http://dx.doi.org/10.1016/j.ijpam.2016.06.003
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was 8% [67].
The LZTR1 gene is located in 22q11.21 and consists of 21
exons and encodes a protein member of the BTB-kelch su-
perfamily. It was suggested that this gene may have a
crucial role in the control of fundamental cellular processes
(such as the cell cycle and the regulation of chromatin
conformation) [68,69].
However, it is worth mentioning that LZTR1 is already
known to be associated with the Schwannomatosis, a form
of neurofibromatosis [70].
2.2.11. A2ML1 (a-2-macroglobulin (A2M)-like-1)
Vissers et al carried out exome sequencing in one Noonan
syndrome case-parent trio and found a de novo mutation
affecting a highly conserved residue of A2ML1 ([OMIM
610627]), encouraging them to screen an additional cohort
of 155 Noonan syndrome patients. This study showed the
involvement of A2ML1 mutations in approximately 1% of
Noonan syndrome subjects negative for the other NS major
genes [71]. A2ML1 is a member of the a-macroglobulin su-
perfamily, localized in 12p13 region with 35 coding exons. It
acts as a protease inhibitor upstream of the MAPK pathway
[72]. Mutations in A2ML1 are said to cause developmental
defects, but the ways in which mutation affects the MAP
kinase pathway needs to be further elucidated [71].
Other genes carrying rare variants in a Noonan syndrome
population were also highlighted recently, in particular,
RASA2, MAP3K8 and SPRY [73].
2.2.12. Other causes
Some studies have suggested other causes of some Noonan
syndrome manifestations that are not related to a partic-
ular gene. For instance, wide-spaced nipples, cryptorchi-
dism and some traits of facial dysmorphia such as
hypertelorism, down slanting palpebral fissures, ptosis and
low-set posteriorly rotated ears are suggested to be the
result of tissue migration disruption or organ displacement
caused by lymphedema at the intrauterine stage. Webbing
of the neck and prominence of the trapezius may result
from cystic hygroma at early intrauterine stages [74].
Recently, it was suggested that the impairment of
testicular function responsible for delayed puberty or
infertility is due to Sertoli and Leydig cell dysfunction
rather than cryptorchidism [75].
The coagulation defect in Noonan syndrome was
explained by the fact that the genes causing Noonan syn-
drome interact with the regulation process of the genes
involved in the coagulation pathway [76].
2.3. The assessment of the mutation rate
In the second part of this review, we gathered and dis-
cussed mutational screening data reported in previous
studies, to produce valid frequencies and authentic con-
clusions about mutational rates in Noonan syndrome ([NS,
OMIM 163950]).
2.3.1. Search strategy
The data gathered were extracted from original articles
published up to now (December 2015) in the “PubMed”,Please cite this article in press as: El Bouchikhi I, et al., Noonan synd
mutation rate, International Journal of Pediatrics and Adolescent Med“ScienceDirect” and “Wiley Online Library” databases using
the following key words:
- “Noonan” in ([Abstract]).
- “Noonan” in ([Title/Abstract]) AND “PTPN11” in
([Title]),
- “Noonan” in ([Title/Abstract]) AND “SOS1” in ([Title]),
and the same goes for the other genes (RAF1, KRAS,
BRAF, NRAS and RIT1).2.3.2. Inclusion criteria
From all of the articles gathered, we considered only
studies comprising genetic screening of patient’s series. We
also considered clinical or endocrinological Noonan syn-
drome studies based initially on genetic screening. The
genes considered in this part of the paper should have been
screened by at least 3 studies meeting the inclusion
criteria.
On the other hand, to determine the exact frequency of
Noonan syndrome mutations, we excluded all data obtained
from the screening of cohorts initially presenting with a
particular condition (i.e., the mutational screening of
Noonan syndrome patients with cardiac hypertrophy). The
data gathered from the 82 included studies are summarized
in Table 1.
2.3.3. The mutational rate of Noonan syndrome-causing
genes
Through the analyzed data (Table 1), we found that
PTPN11 is the most studied gene in Noonan syndrome
populations (29 studies vs. 16 studies or less for other
genes). This may be because PTPN11 was the first gene of
the RAS MAPK pathway to be highlighted in 2001, whereas
the second gene involved (KRAS ) as found 5 years later,
followed by SHP-2. Indeed, the second gene, KRAS, was
known beforehand to be involved in malignancy disorders
through somatic mutations, while its germline mutations
were associated for the first time with Noonan syndrome in
2006.
Then, in 2007, three genes were highlighted, (SOS1,
RAF1 and MAP2K1), after which the other RAS/MAP kinase
genes, BRAF, NRAS and RIT1, were proven to be involved in
Noonan syndrome in more recent, in 2009, 2010 and 2013,
respectively.
It should be noted that the chronology of the gene
identification does not consistently occur in the “more
involved” to “less involved” direction. Indeed, RIT1, which
was discovered in 2013, was proved to be involved in 8% of
cases. This frequency is much higher than the frequency of
some genes (BRAF, KRAS and NRAS ) that were found first,
while their incidences do not exceed 3% (2.3%, 2.8% and
0.8%, respectively).
The first most common genetic cause of Noonan syn-
drome is still PTPN11 mutations that are observed in 42.5%
of Noonan syndrome patients. Those mutations constitute
52.6% of all mutations detected up to now (Table 1).
The second most-involved gene is SOS1, which is altered
in 16.4% of patients. On the other hand, we found that RIT1
and RAF1 have the same prevalence (8%) and are the third
most-involved genes.124
rome-causing genes: Molecular update and an assessment of the
icine (2016), http://dx.doi.org/10.1016/j.ijpam.2016.06.003
4Table 1 Summary of the prevalence of Noonan syndrome-causing genes through previous studies.
Genes N of mutated
subjects/total of
subjects (% of mutations)
% of gene
in genetic etiology
First year of
gene study
N of studies References
PTPN11 814/1917 (42.5%) 52.6 2001 29 [19,24,34,35,58,77,83e105]
SOS1 242/1472 (16.4%) 20.3 2007 16 [19,34,36,39,43,58,78,97,98,102e108]
RIT1 31/383 (8%) 10 2013 4 [51,53,54,73]
RAF1 76/961 (8%) 10 2007 11 [34,55e58,78,98,103,105,107,108]
KRAS 31/1087 (2.8%) 3.4 2006 11 [46e48,58,65,89,98,102,103,105,108]
BRAF 19/815 (2.3%) 2.8 2009 7 [34,63,78,98,103,105,108]
NRAS 10/1213 (0.8%) 1 2010 4 [50,109e111]
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IJPAM84_proof ■ 17 August 2016 ■ 7/10Taken together, PTPN11, SOS1, RAF1 and RIT1 cover 93%
of reported mutations (Table 1). Therefore, these genes
should be systematically considered in the genetic diag-
nosis of Noonan syndrome.
Among the RAS subfamily members of the RAS/MAP ki-
nase pathway reported in Noonan syndrome, RIT1 seems to
be the most involved gene compared with KRAS and NRAS,
which have the lowest frequency among all reported cases
(2.8% and 0.8%, respectively); however, among RAF family
members, RAF1 is the most involved gene compared to
BRAF (8% versus 2.3%, respectively). Among these two
families, neither HRAS nor ARAF were reported to cause
Noonan syndrome. These divergences should attract more
attention from researchers.
It is worth mentioning that there were no mutations in
the SHOC2, RRAS and CBL genes in Noonan syndrome pa-
tients. These genes were reported to be involved in
Noonan-like syndrome (NLS) only.
2.4. Inheritance and genetic counseling
Noonan syndrome is a common disorder that could occur as
a sporadic condition or can be inherited in an autosomal
dominant pattern. In the latter case, the affected parent
who transmits the disorder is predominantly the mother.
This may be explained by the adverse impact of Noonan
syndrome on male fertility [7,13,79]. However, rare auto-
somal recessive cases of Noonan syndrome with consan-
guineous parents have also been reported [80].
When there is molecular evidence in one Noonan syn-
drome child, the clinical and molecular evaluation of par-
ents becomes primordial in the determination of
recurrence risks. In Noonan syndrome-causing genes with
heterozygous mutations, the recurrence risk in one genet-
ically affected parent is 50% per each pregnancy, while in
an unaffected parent with Noonan syndrome child, the
recurrence risk in subsequent pregnancies is very low,
approximately 1e5% owing to putative germline mosaicism.
The Noonan syndrome patient and their family should be
made aware of the consequences of some Noonan syn-
drome features that may arise or complicate with adult-
hood, such as fertility problems in cryptorchidism cases and
cardiac and hematological complications, which need
rigorous follow-up [81].
The de-novo PTPN11 mutations are known to be more
recurrent in Noonan syndrome. Tartaglia et al suggested
that de-novo mutations have a predominantly paternalPlease cite this article in press as: El Bouchikhi I, et al., Noonan synd
mutation rate, International Journal of Pediatrics and Adolescent Medorigin. They also demonstrated that the paternal average
age in sporadic Noonan cases was significantly higher than
that of the general population [82].
3. Conclusion
Noonan syndrome is a common multigenic disease. Its
clinical side has been profoundly discussed by several re-
searchers and diagnostic guides as support has been
developed. This review completes the efforts of re-
searchers focusing on the genetic etiology side of this
syndrome and explains the physiopathological intervention
of different genes in the manifestation of Noonan syndrome
traits. In the second part, this paper provides pediatricians
and geneticists with the mutational prevalence of genes
involved in Noonan syndrome, which was deduced from the
analysis of most studies carried out so far.
The result of this prevalence analysis leads to inter-
esting conclusions, in particular, the high mutation rates
observed in PTPN11, SOS1, RAF1 and RIT1, which cover
93% of reported mutations, suggesting that those genes
should be systematically considered in the genetic diag-
nosis of Noonan syndrome. Secondly, we draw attention to
the significant differences observed between mutational
rates in genes of the same family (genes of the same level
of the cascade). The explanation of this divergence
and the other points discussed in this review may lead to
new insights in the genetic research field of Noonan
syndrome.
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